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Abstract  
Background: Although Health Technology Assessment (HTA) is increasingly used to support evidence-
based decision-making in health care, several barriers and facilitators for the use of HTA have been 
identified. This best-worst scaling (BWS) study aims to assess the relative importance of selected barriers 
and facilitators of the uptake of HTA studies in Austria. 
Methods: A BWS object case survey was conducted among 37 experts in Austria to assess the relative 
importance of HTA barriers and facilitators. Hierarchical Bayes estimation was applied, with the best-
worst count analysis as sensitivity analysis. Subgroup analyses were also performed on professional role 
and HTA experience.  
Results: The most important barriers were ‘lack of transparency in the decision-making process’, 
‘fragmentation’, ‘absence of appropriate incentives’, ‘no explicit framework for decision-making process’, 
and ‘insufficient legal support’. The most important facilitators were ‘transparency in the decision-making 
process’, ‘availability of relevant HTA research for policy makers’, ‘availability of explicit framework for 
decision-making process’, ‘sufficient legal support’, and ‘appropriate incentives’. 
Conclusion: This study suggests that HTA barriers and facilitators related to the context of decision 
makers, especially ‘policy characteristics’ and ‘organization and resources’ are the most important in 
Austria. A transparent and participatory decision-making process could improve the adoption of HTA 
evidence.  
 







In light of the resource scarcity and budget constraints that health systems are facing, healthcare-related 
decisions have to be made on the optimal and efficient allocation of resources [1]. Within this context, a 
trend towards evidence-based decision-making can be observed which reinforces the need to base 
resource allocation decisions on rational criteria, including (cost-)effectiveness, efficiency [2] and equity 
[3] considerations. The importance of the utilization of health-related research in policy-making has been 
widely recognized [4] and is increasingly based on Health Technology Assessment (HTA). HTA is a policy-
oriented form of research designed to examine the consequences of the introduction of health care 
technologies and interventions [5, 6, 7]. It aims to inform policy and clinical decision-making in health care 
[7] by assessing the medical, social, economic and ethical impact of the use of health technology [8].  
 
Although HTA and its branch of economic evaluation is widely recognized as being an insightful tool to 
achieve health care efficiency, the impact on decision-making could still be limited [2]. The extent to which 
HTA information is utilized in decision-making varies across European countries, mainly due to the 
countries’ different governmental and organizational structures in the health system [9, 10, 11]. In Austria, 
HTA research has been introduced in the 1990s. Since the establishment of the ‘Ludwig Boltzmann 
Institute for Health Technology Assessment’ (LBI-HTA) in 2006, HTA research has gained greater 
prominence by providing scientific support for decision-making in the Austrian health care sector [12, 13]. 
Nevertheless, Austria is a latecomer in implementing HTA evidence as decision-support tool compared to 
other countries [13, 14] and the use of HTA information by different national stakeholders still has 
potential for increase. 
 
Since the gap between HTA research and policy uptake is often described as an issue [9, 15], several 
studies have investigated and identified multiple barriers of and incentives for the use of HTA information 
within the decision-making process internationally [1, 5, 15, 16, 17]. For instance, reported barriers 
include ‘having no time/opportunity to use research evidence’, ‘difficulties in transferring budgets’ or ‘lack 
of credibility of HTA studies [5, 15], while reported facilitators include ‘availability of and access to HTA 
findings’, or ‘explanation of the practical relevance of results’ (e.g. actual cost savings) [15, 18]. However, 
there is as paucity of research that assesses the most important barriers and facilitators. Only one Dutch 
best-worst scaling (BWS) study was identified suggesting that barriers and facilitators related to ‘policy 
characteristics’, and ‘organization and resources’ were particularly important [19]. Little is however 
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known on how the Dutch BWS study results could be transferable to other countries. Moreover, in most 
of the published international studies, little attention has been given to the perspective of knowledge 
users of HTA evidence, i.e. policy makers [5, 16]. Hence, it is of great relevance to also include knowledge 
users and investigate their perception of the practicability of HTA as well as their priorities [5, 15]. For 
Austria, to optimize and increase the usage of HTA it is of great interest and relevance to elicit the most 
important barriers and facilitators to the adoption of HTA evidence by national stakeholders. Only when 
considering the various reasons for limited usage can a better management and utilization of scarce health 
care resources through improved uptake of HTA be realized [5]. 
 
The aim of this BWS study was therefore twofold: (1) to collect and analyse data on the relative 
importance of selected barriers and facilitators of the uptake of HTA studies in Austria, and (2) to explore 
differences in perception between different stakeholder groups. The study addresses the question which 
factors are considered most important and least important by relevant stakeholders, including Austrian 
policy makers, health professionals and HTA researchers. Such understanding will provide important 
insights for a better matching of HTA and user needs, and thereby potentially help strengthening the 






2.1 Best-worst scaling  
 
The BWS technique, which is a type of conjoint analysis, is becoming increasingly popular to elicit 
preferences in health care [20, 21]. BWS, compared to the traditional and more widely applied discrete 
choice experiment (DCE), presents an alternative preference elicitation method [22] that can resolve some 
of the limitations of the DCE technique [23]. For example, BWS is relatively simple to understand and thus 
supposed to reduce the cognitive burden for respondents and facilitates the evaluation of maximum-
difference questions. BWS also overcomes the traditional ‘pick one’ task used in DCE [22] by eliciting 
additional information on both the most and least preferred option. Additionally, BWS possesses the 
ability to embrace a larger set of factors to determine preferences [23].  
 
In this study, we used a BWS object case (case 1), also known as attribute case [22], to quantitatively 
assess the relative importance of an exhaustive list of nationally relevant barriers and facilitators to the 
adoption of HTA information. Respondents were asked to make judgements on the most and least 
important factor out of five elements of a choice set aiming for the analysis of preferences regarding a set 
of attributes/factors. This trade-off technique applied in the BWS survey constituted of two parts, one 
part addressing barriers and one part addressing facilitators.  
 
2.2 Identification of attributes  
 
The majority of attributes assessed in this study were based on a master list of 22 barriers and 19 
facilitators which were identified in an international scoping review conducted for a comparable Dutch 
BWS study [19]. Further details on the scoping review can be found in Cheung et al. (2017) [19]. To take 
the specificity of the Austrian health care system and decision-making context into consideration, 
additional factors were identified through a scoping review of relevant peer-reviewed and grey literature 
on HTA in Austria conducted by CF and SM. This search in PubMed, Web of Science, google scholar and 
on websites of key stakeholders led to a total of 13 relevant studies. The additionally generated list of 
factors was discussed within the project group and further validated by three national experts (one policy 
maker and two HTA experts). This led to a final master list of 25 barriers and 21 facilitators for the BWS 
experiment. Appendix Table 1 lists these factors. As shown in appendix Table 2, these barriers and 
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facilitators can be classified into three main categories and six sub-categories according to Brouselle and 
Lessard (2011) and Oliver et al. (2014) [2, 15]. The three main categories relate to decision-maker, context-
related and methodology-related factors. The six sub-categories (themes) include ‘policy characteristics’, 
‘organization and resources’ ‘contact and collaboration’, ‘research and researcher characteristics’, ‘policy 
makers characteristics’ and ‘other’ [15]. 
 
2.3 Survey participants  
 
A purposive sampling method [24] was applied to recruit relevant stakeholders in Austria, including policy 
makers, health professionals, HTA experts (i.e. research associates in the field of HTA and members of 
specific HTA research groups or institutes; PhD students were excluded), and the pharmaceutical industry, 
for participating in the survey. Important stakeholders with an interest were selected. The list of potential 
participants contained an equal sample size of experts from all stakeholder groups to potentially allow for 
an overall balanced assessment of HTA barriers and facilitators from different stakeholder perspectives.  
 
The sample selection process was based on a systematic assessment of national HTA key players through 
several channels. Firstly, all HTA institutions listed in the Austrian HTA Guide [25] were included. Secondly, 
the list of potential participants was complemented with institutions and contacts provided by national 
experts of the Austrian health care system, including members of the Department of Health Economics at 
the Medical University of Vienna. Additional stakeholders were also informed by institutions identified in 
a recent systematic literature review of published economic evaluations in Austria [26, 27]. Thirdly, 
relevant experts were selected based on the literature review conducted for the identification of Austria-
specific barriers and facilitators. 
 
Participant contact information was collected between December 2016 and April 2017. The final list of 
participants consisted of a total of 96 experts.  
 
2.4 The best-worst scaling survey  
 
The Sawtooth Software’s SSI® Web platform was used to design the BWS survey. Fractional, efficient 
designs were applied, characterized by: 1) orthogonality (factors were shown and paired an approximately 
equal number of times), 2) minimal overlap (minimizing the number of times each factor appears within 
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the same set across the design), 3) positional balance (factors appear approximately an equal number of 
times in each position), 4) connectivity (factors are directly or indirectly linked), and 5) stability. Four 
different versions of the questionnaire were generated for each part of the BWS experiment, i.e. four 
versions for barriers and four versions for facilitators. 
 
The online survey was designed via Qualtrics® and consisted of a self-administered questionnaire. The 
questionnaire included mainly closed-ended questions and two open-ended question providing 
participants the opportunity to give further comments on the survey content. Demographic and 
professional characteristics (gender, age, professional role, HTA experience) were assessed at the 
beginning. Each participant was asked to define their professional role by choosing one out of four 
different roles, including policy maker, health professional, research associate in the field of HTA or 
evidence-based research, and specific HTA research group or institute. To allow for a comparison with the 
findings of the recent Dutch BWS study [19], the categorization of professional roles was set-up similarly. 
Hence, stakeholder groups from the pharmaceutical industry were not indicated separately and due to 
the anonymous set-up of the survey, it remains unclear how many stakeholders from this subgroup 
eventually participated in the survey. 
 
The relative importance of each individual factor was assessed per participant using 15 choice sets for 
barriers (the barriers questionnaire) and 13 choice sets for facilitators (the facilitators questionnaire), each 
composed of five factors from the master list. Participants were randomly assigned to one out of the four 
versions of the barriers questionnaire and one out of the four versions of the facilitators questionnaire 
while the order of the survey parts (barriers/facilitators) was also randomly allocated. At the end of the 
barriers and facilitators parts, participants were asked to rate the difficulty of completing the choice sets 
based on a Likert-scale (1=very easy, to 7=very difficult).  
 
The BWS survey was sent out via Qualtrics® in May 2017. It was active for an initial period of two weeks 
and a weekly reminder was distributed out via Qualtrics®. Respondents were assured anonymity 
throughout the survey procedure.  
 




All completed surveys were included in the data analysis. In previous BWS object case studies, the 
Hierarchical Bayes (HB) estimation has been frequently used to analyse data [21, 28]. Therefore, the HB 
estimation was used as the main analysis method in this study using the Sawtooth Software’s SSI® Web 
platform. The calculation of the mean relative importance score (RIS) with its 95% confidence interval, 
generated by the HB estimation, allowed ranking the factors from the most and least important. The 
higher the RIS score, the higher the relative importance of a factor (barrier or facilitator) was found.  
 
In addition to the HB estimation, the best-worst count analysis was conducted as a secondary (sensitivity) 
analysis. The best-worst count analysis, which is a relatively simpler approach to analyse BWS object case 
data [21], is also increasingly applied in BWS object case studies [21]. Accordingly, we calculated scores 
based on the number of times an attribute was selected as the best and the worst across all questions 
included in the survey [29, 30]. The number derived for the least important factor was subtracted from 
the count for the most important factor (total(best)-total(worst)) [31]. The obtained number was divided 
by the number of times the factor appeared in the survey, creating a scale (-1 to +1) in which a high score 
indicates that the factor is more important to the respondent [29, 30].  
 
The demographic and professional characteristics of the participants were described and used for further 
analyses. Subgroup analyses according to professional roles (policy makers vs. health professionals/HTA 
experts, including research associates in the field of HTA or evidence-based research, and members of 
HTA research groups or institutes) and HTA experience (based on the self-reported performance of an 
HTA study) were performed to assess whether the perception on the importance of factors differed by 
these stakeholder characteristics. With respect to the subgroup analysis on professional roles, the 
distinction between policy makers and health professionals/HTA experts assured an emphasis on the 
importance of the policy makers’ role, which is considered a distinct and vital stakeholder group regarding 
the uptake of HTA evidence in Austria. Regarding HTA experience, health professionals and HTA experts 
were considered a homogenous group compared to policy makers, hence the latter were excluded in the 
subgroup analysis evaluating the influence of HTA experience on the perception of HTA barriers and 
facilitators. Statistical analyses were conducted in SPSS (version 23), including Chi-square tests and one-






3.1 Participant characteristics 
 
In total, 53 participants started the survey. Out of these, 37 participants (69.8%) completed the survey 
and were included in the analysis, resulting into an overall response rate of 38.5% (37/96). Seven 
incomplete responses of those who started the survey contained information on the demographic and 
professional characteristics; no significant differences were found between these participants (n=7) and 
those who completed the survey (n=37).  
 
Seventeen survey participants were male (45.9%) and 20 participants were female (54.1%). The age of the 
respondents ranged from 20-29 years (5.4%, n=2), 30-39 (24.3%, n=9), 40-49 (32.4%, n=12), 50-59 (24.3%, 
n=9) to 60-69 years (13.5%, n=5). There were six policy makers (16.2%), five health professionals (13.5%), 
21 research associates (56.8%) and five members of HTA research groups or institutes (13.5%). In terms 
of HTA experience, almost three-quarter of the participants (n=27; 73.0%) self-reported having conducted 
or contributed to an HTA study at least once during their professional career, whereas ten participants 
(27.0%) reported that they had not previously conducted an HTA study.  
 
Participants rated both BWS experiment parts as medially difficult on a 7-point Likert scale (barriers: 
mean=4.02, SD=1.55; facilitators: mean=4.08, SD=1.66). Six comments were provided in the open-ended 
questions fields, either related to the difficulty of completing the choice tasks, pointing out the lacking 
availability of HTA evidence or emphasizing the importance of a regulatory framework for HTA in Austria. 
 
The overall fit statistic (barriers=0.45; facilitators=0.48) of the responses was considered good. All 
respondents had an overall fit statistic higher than 0.25 and were thus all included in the analysis [32]. 
 
3.2 Relative importance of HTA barriers  
 
Figure 1 illustrates the RIS of the barriers and points at a visual cut-off point (RIS=6.50) that can be 





The five most important barriers (RIS>6.50) to the uptake of HTA in Austria (n=37) were ‘lack of 
transparency in the decision-making process’, ‘fragmentation’ (difficulties in moving resources/budgets 
from one sector to another), ‘absence of appropriate incentives for implementation of cost-effective 
interventions’, ‘no explicit framework for decision-making process’ (that uses HTA evidence), and 
‘insufficient legal support’ (lack of legal or legislative support to the use of HTA). 
 
The best-worst count analysis, which was conducted as a sensitivity analysis, yielded similar results 
regarding the ranking order of the most important barriers (see Appendix Table 3). 
 
Figure 1. Ranked barriers of the uptake of HTA (n=37).  
The RIS in boxes indicate the most important barriers (RIS>6.50). 
 
Based on a categorization of all selected barriers from the list of factors included in this study (n=25), 
context-related factors (n=12), referring to the sub-categories ‘policy characteristics’ and ‘organization 
and resources’ [15] comprised overall the highest number of factors, followed by methodology-related 
(n=7) and decision-maker related (n=6) factors (see Figure 1 and Appendix Table 2). Following the 
classification of the five most important barriers revealed that ‘context-related factors’ [2] were the most 
dominant themes. The least important barriers determined in this study were methodology-related 
factors that refer to the sub-category ‘research and researcher characteristics’ [15], and include barriers 
such as ‘no guidelines’ (absence of adequate/reliable HTA guidelines) and ‘inadequate presentation 
format’ (HTA reports overly long, too theoretical or abounding in technical jargon). 
 
The subgroup analysis demonstrated two statistically significant (p<0.05) differences between policy 
makers and health professionals/HTA experts. As shown in Figure 2, the factor ‘lack of qualified human 
resources to conduct or understand relevant HTA research within the policy organization’ was considered 
more important by policy makers. The factor ‘no explicit framework for decision-making process’ was 
perceived as more important by health professionals/HTA experts. Although not statistically significant, 
additional differences in perception are indicated in Figure 2. It seems that ‘absence of appropriate 
incentives for implementation of cost-effective interventions’ and ‘insufficient legal support’ (lack of legal 
support or legislative support to the use of HTA) were more important for health professionals/HTA-
experts. In contrast, policy makers emphasized that ‘lack of transparency of HTA research findings’ (the 
process as to how presented research findings emerged is not clear) may be an important barrier to the 
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use of HTA evidence as well as encountering ‘insufficient quality of HTA research findings’ (quality not 
according scientific requirements). 
 
Figure 2. HTA barriers by policy makers (n=6) and health professionals/HTA experts (n=31). 
* and boxes indicate a statistically significant factor, p<0.05. 
 
The other subgroup analysis revealed two statistically significant (p<0.05) differences between 
participants who reported that they had already conducted an HTA study in their professional career and 
participants who did not (results not shown, n=31). ‘Lack of longstanding relation between 
professionals/policy makers and researchers’ (mean=3.18, SD=2.78 vs. mean=5.70, SD=3.04, F=4.29) and 
‘no access to relevant HTA research (poor dissemination) for policy makers’ (mean=1.32, SD=1.00 vs. 
mean=2.96, SD=3.09, F=5.32) were more important for health professionals and HTA experts without 
applied experience in conducting an HTA study.  
 
3.3 Relative importance of HTA facilitators  
 
Figure 3 presents the RIS of the facilitators. The factors ‘transparency in the decision-making process’, 
‘availability of relevant HTA research for policy makers’, ‘availability of explicit framework for decision-
making process’ (that uses HTA evidence), ‘sufficient legal support’ (legal or legislative support to the use 
of HTA), and ‘appropriate incentives for implementation of cost-effective interventions’ were considered 
as being most important for Austrian experts (RIS>6.50).  
 
Similarly to the findings of HTA barriers, the best-worst count analysis resulted in a comparable ranking 
order of the most important facilitators (see Appendix Table 3). 
 
Figure 3. Ranked facilitators of the uptake of HTA (n=37). 
The RIS in boxes indicate the most important facilitators (RIS>6.50). 
 
Classifying all facilitators listed in this study shows that overall, context-related factors (n=10) were 
highest in number, followed by decision-maker related (n=6) and methodology-related factors (n=5) (see 
Figure 3 and Appendix Table 2). Categorizing the five most important facilitators into categories and sub-
categories revealed that here also ‘context-related factors’ [2] were the most important. The least 
11 
 
important HTA facilitators assessed in this study were the following: ‘appropriate HTA topic-finding 
process’ (context-related factor) and ‘availability of guidelines’ (the availability of adequate/reliable HTA 
guidelines) (methodology-related factor).  
 
The subgroup analysis revealed three statistically significant (p<0.05) differences between policy makers 
and health professionals/HTA experts (Figure 4). ‘Sufficient awareness within the organization to the 
relevance of HTA’ and ‘appropriate HTA topic-finding process’ were more important for policy makers 
than for health professionals/HTA experts while ‘appropriate incentives for implementation of cost-
effective interventions’ were perceived more relevant for health professionals/HTA experts than for policy 
makers. Figure 4 shows all (also statistically non-significant) differences in perception regarding facilitators 
to the use of HTA evidence in decision-making. Policy makers found ‘sufficient support by stakeholders’ 
(policy maker’s perception of insufficient support by end-users) as an important facilitator. Contrary, 
health professionals/HTA experts perceived that ‘sufficient financial resources to conduct relevant HTA 
research’ presents an important facilitator to the adoption of HTA evidence.  
 
No statistically significant difference was found according to HTA experience.  
 
Figure 4. HTA facilitators by policy makers (n=6) and health professionals/HTA experts (n=31). 
* and boxes indicate a statistically significant factor, p<0.05.  
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4. Discussion  
 
This study identified the relative importance of barriers and facilitators to the uptake of HTA evidence in 
Austria as well as the differences in perception between policy makers, and health professionals/HTA 
experts in this respect. Our findings indicate that especially the Austria-specific HTA barriers and 
facilitators had a greater relative importance compared to the internationally validated HTA factors.  
 
Many of the identified most important HTA barriers and facilitators were opposites. For instance, 
‘appropriate incentives for implementation of cost-effective interventions’ was perceived as one of the 
most important facilitators, while ‘absence of appropriate incentives for implementation of cost-effective 
interventions’ was an important barrier. Classifying the five most important barriers and facilitators into 
categories [2] revealed that ‘context-related factors’ were the most important, which refer to the decision 
maker’s context including organizational, political, budgetary and social factors [2]. Similarly to our 
findings, ‘context-related factors’ were identified as being the most important barriers and facilitators in 
a recent Dutch BWS study [19]. Therein, ‘policy characteristics’ (e.g. ‘explicit framework for decision-
making process that uses HTA evidence’) and ‘organization and resources’ (e.g. ‘availability of relevant 
HTA research for policy makers’) were acknowledged to be the most significant sub-categories [19]. In 
accordance with our findings, Oliver et al. (2014) [15] suggest that factors relating to ‘organization and 
resources’ (e.g. ‘availability of and access to research/improved dissemination’) are most frequently 
reported barriers and facilitators for the use of HTA evidence. Especially, the high importance of the 
‘availability of relevant HTA research for policy maker’ found in this study points out that (public) 
investment to help produce relevant HTA research in Austria, particularly matching the user needs of 
policy makers needs to be encouraged. This indication was supported by the comment made by a survey 
participant who emphasized the currently lacking availability of HTA evidence that is useful not only for 
the seller of a health technology, but for the decision maker. Contradictory to our findings, Oliver et al. 
(2014) [15] concluded that ‘policy characteristics’ such as legal support to the use of HTA and explicit 
framework for the use of HTA evidence were scarcely reported as factors affecting the uptake of HTA 
information internationally. In contrast, the least important factors determined in this study were related 
to ‘research and researcher characteristics’ [15], including i.e. absence/availability of HTA guidelines and 




‘(Lack of) transparency in the decision-making process’ within the health care sector was found to be the 
most important barrier and facilitator to the adoption of HTA evidence in Austria. This factor was scarcely 
reported internationally and seems to be Austria-specific. This finding supports the rationale behind the 
assessment of country-specific factors to take into account the national health care and HTA landscape as 
well as the specific features of governmental, legal and organisational structures in the health care 
decision-making process. In addition, the high importance of both ‘transparency in the decision-making 
process’ and ‘explicit framework for decision-making process’ revealed, in line with the cross-sectional 
survey by Mochón et al. (2017) [11], that a transparent and comprehensive HTA system is an important 
prerequisite for the successful adoption of HTA evidence. Our study suggests that based on the perception 
of the surveyed stakeholders, such a system does not exist in Austria. Reasons for this may be, on the one 
hand, the unavailability or insufficient quality of local HTA input data, and on the other hand, the fragile 
structure/framework in HTA decision-making [11]. The former point was also supported by a survey 
participant who emphasized the availability of high quality input data as a crucial prerequisite to produce 
high quality HTA evidence (“garbage in, garbage out”). Mochón et al. (2017) [11] advise that improving 
transparency in the HTA decision-making process needs to be encouraged, while considering the necessity 
of an equilibrium between transparency and confidentiality. In this respect, our finding is in accordance 
with an earlier Austrian report by Schumacher and Zechmeister (2011) [33] and emphasizes that improved 
transparency in the decision-making processes is urgently needed. On the other hand, the report by 
Schumacher and Zechmeister additionally indicates that some evidence for a standardized inclusion of 
HTA results in the decision-making processes has been existing in Austria, linked “with tendencies to 
[enhance] transparency” [33]. Our subgroup analysis demonstrated that the relative importance of having 
‘no explicit framework for decision-making process’ (that uses HTA evidence) was considered high 
dominantly by health professionals/HTA experts, implying that policy makers may have failed to consider 
this issue sufficiently.  
 
‘Fragmentation’, capturing the difficulties in moving resources/budgets from one sector to another (i.e. 
fragmentation of responsibilities and competencies for HTA) represented the second most important 
rated barrier to the adoption of HTA. Indeed, the Austrian health care system is characterized by decentral 
decision and funding structures and a strong sectoral focus of relevant funding bodies [14]. The results of 
this BWS study confirm that the structure currently in place for implementing HTA evidence might need 




‘(In)sufficient legal support’ ((no) legal or legislative support to the use of HTA) was among the most 
important HTA barriers and facilitators in our study. This indicates, in line with Chinitz (2004) [9] and 
Mochón et al. (2017) [11] that the governance and organization of HTA systems are essential factors for 
influencing the uptake of HTA. Internationally, countries which reported having legislation establishing 
the use of HTA as mandatory, showed greater support of HTA evidence in the decision-making process 
[11]. Since health care in Austria is considered as the responsibility of public policy [13], a stronger 
centralization of HTA could potentially increase the impact on HTA adoption and its usage at both national 
clinical and policy level [9]. Consequently, legislative support for using HTA could possibly enhance the 
extent to which HTA evidence is adopted in Austria. This was also pointed out by a study participant, 
confirming that as long as there was no regulatory framework requiring federal states or health insurance 
funds to consider HTA evidence in their decision-making process, also little funding would be invested in 
the production of HTA reports by public authorities. However, at this point, it is worth mentioning that 
some legislative support of HTA usage can be observed with Article 15a of the Austrian Federal 
Constitution Law (§17(4), 2013) calling for a “uniform framework of cost-benefit analyses and evidence-
basing (HTA) for diagnosis and treatment methods (including health promotion, screening and vaccination 
programs)” [34]. 
 
Further subgroup analyses revealed several differences in the perception of stakeholders based on their 
professional roles and HTA experience. For example, ‘lack of qualified human resources’ (to conduct or 
understand relevant HTA research) was perceived as more relevant by policy makers. This finding stresses 
that profound understanding of HTA studies is an important prerequisite for adopting the derived 
evidence-based recommendation. Closely related to this, ‘sufficient awareness’ (within the organization 
to support the relevance of HTA) needs to be promoted. Moreover, an ‘appropriate HTA topic-finding 
process’, i.e. the existence of a participatory topic-finding system, was found to be more important for 
policy makers and points at a perceived gap in this respect. This means that the existence of a participatory 
topic-finding system, which allows regular and problem-relevant prioritization of HTA topics, is less 
essential for health professionals/HTA experts. Accordingly, it appears that the producers of HTA evidence 
may need to enhance their efforts to involve policy makers in their topic-finding process. Since 
‘appropriate incentives for implementation of cost-effective interventions’ was more important for health 
professionals/HTA experts, reinforcing the factor ‘contact and collaboration’ (e.g. by improving 
longstanding relations between professionals/policy makers and researchers) could potentially lead to a 




4.1 Strengths and limitations  
 
Previous studies have investigated multiple barriers and facilitators for the use of Health Technology 
Assessment evidence within the decision-making process [1, 5, 15, 16, 17], however, few studies have yet 
quantitatively assessed the most important barriers and facilitators and involved decision-makers in 
addition to HTA experts [19, 33]. To our knowledge, this is the first study assessing the relative importance 
of barriers and facilitators to the use of HTA in Austria, i.e. a country which can be considered a latecomer 
in implementing HTA evidence as decision-support tool compared to other countries [13, 14]. In this study, 
both the initial international master list of factors and the additional list of Austria-specific factors were 
based on a literature review and validated by (Austrian) policy makers and HTA experts. The review of 
peer-reviewed and grey literature to identify Austria-specific factors constitutes important strength of this 
study. Accordingly, this allowed for a comprehensive assessment of HTA barriers and facilitators taking 
into account the country-specific institutional background, which should also be considered in future 
research. The factor list assessed substantially extends the six HTA impact indicators included in the earlier 
Austrian report by Schumacher and Zechmeister [33]. In our study, participants were selected from all 
relevant HTA institutions and an equal sample size from each stakeholder institution was included to 
potentially allow for an overall balanced assessment of HTA barriers and facilitators from different 
stakeholder perspectives. Moreover, an experienced sample partook in this survey with most participants 
(n=27, 73%) reported having conducted or contributed to conducting an HTA study during their 
professional career. Although this information is based on self-reported data and needs to be interpreted 
with caution, it suggests that this BWS study captures an insider perspective within the Austrian HTA field. 
Finally, two statistical methods were applied in this BWS study, yielding similar results and hence 
confirming the robustness of our findings.  
 
There are, however, a number of limitations worth mentioning. Firstly, as some of the factors used in the 
BWS study were tailored to the Austrian institutional background, the findings of this study may not 
necessarily be generalizable to other countries, especially countries showing differences in characteristics 
of their HTA decision-making process (e.g. UK) [9]. At the same time, it is unclear if similar barriers and 
facilitators would be identified in countries with a similar tradition in HTA uptake as in Austria. Future 
research should look into this. Secondly, the overall results of the relative importance of HTA barriers 
(Figure 1) and facilitators (Figure 3) may be distorted due to the overrepresentation (e.g. HTA researchers) 
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and underrepresentation (e.g. policy makers) of different stakeholder groups participating in the survey. 
Findings were therefore also presented by stakeholder groups (Figure 2, Figure 4). Thirdly, one may argue 
that the different study participants were influenced in their perceptions on the relative importance of 
different factors by underlying administrative variables such as if HTA reports are mandatory for a formal 
decision on pricing and reimbursement of a technology. At the same time, there is no such mandatory 
requirement to use HTA evidence in decision-making in Austria [35, 36] and albeit being a ‘fourth hurdle’ 
for innovative pharmaceuticals [37], economic evaluations also play a minor role in practice [38]. 
Expectedly, however, e.g. survey participants from the pharmaceutical industry might be influenced in 
their responses by this context, while the extent of their survey participation remains unclear. 
Consequently, formal assessment of this hypothesis is not possible and would have to be addressed by 
future research. Fourthly, study participants may not have been familiar with the BWS set-up as it 
represents a relatively novel method. This may have led to some respondents opting out the survey and 
hence a non-response bias. Although it is argued that a decreased cognitive burden is placed on 
participants facing a BWS choice format, the available evidence is not yet conclusive [39]. Finally, while 
this BWS study was a vital first step towards systematically identifying the most relevant barriers and 
facilitators for the uptake of HTA in Austria, further in-depth insights would be needed to understand how 
current processes could be improved. To this end, e.g. qualitative research including expert interviews on 
the identified main factors could be conducted to gain a more differentiated understanding of the 
underlying mechanisms.  
 
4.2 Policy making implication and recommendations 
 
Eliciting preferences in healthcare and adopting this knowledge to improve the use of HTA evidence in 
decision-making processes are important but have been scarcely performed. In this context, BWS showed 
a rapid development in health applications to elicit powerful stakeholder (public) preferences [21, 39, 40]. 
Regarding the adoption of HTA information, more in-depth insights into barriers and facilitators are 
needed to enhance the use of HTA in decision-making. Thus, identifying firstly the most important barriers 
and facilitators as done in this study seems a pre-requisite to the enhancement of both evidence-based 
decision-making and policy making. Once investigated, new methods need to be considered to improve 
policy priorities and decision-making support for HTA uptake to overcome the barriers described [15]. For 
instance, providing the required impulse at national level to further establish an explicit framework or 
even legal support for including HTA in the decision-making process on different levels based on fully 
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transparent and formalized criteria seems to be an important step for Austria. The basis for Austria to 
improve their formal HTA process could be a cross-country comparison and learning from the experiences 
of other countries. Such insights could improve the application of HTA evidence and strengthen the 
implementation of cost-effective interventions in light of resource scarcity and budget constraints.  
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5. Conclusion  
 
This study aimed to quantitatively analyse the relative importance of barriers and facilitators regarding 
the use of HTA evidence in Austria. HTA barriers and facilitators related to the context of decision makers, 
including ‘policy characteristics’ and ‘organization and resources’ were found to be particularly important. 
Considering the importance of ‘policy characteristics’ factors, a higher emphasis should be set at the 
national level towards establishing an explicit framework or even legal support for including HTA evidence 
in health care decision-making in Austria. Hereby, the focus should lie on bridging the gap between HTA 
research and policy uptake on the one hand, and on ensuring a more transparent and participatory 




 Previous studies have investigated multiple barriers and facilitators for the use of Health 
Technology Assessment (HTA) evidence within the decision-making process internationally, 
however, few studies have yet quantitatively assessed the most important barriers and facilitators 
and involved decision-makers in addition to HTA experts. 
 Results from this best-worst scaling (BWS) online survey indicate that HTA barriers and facilitators 
related to the context of decision-makers, including ‘policy characteristics’ (e.g. (lack of) 
transparency in the decision-making process) and ‘organization and resources’ (e.g. (absence of) 
appropriate incentives for implementation of cost-effective interventions) are particularly 
important in Austria.  
 Subgroup analyses (policy makers vs. health professionals/HTA experts) show that the relative 
importance of having ‘no explicit framework for decision-making process’ as a barrier was more 
important for health professionals/HTA experts than for policy makers. Accordingly, policy makers 
may have failed to recognize this issue sufficiently and to provide an explicit framework to include 
HTA evidence in decision-making. 
 A higher emphasis should be set towards establishing an explicit (legal) regulatory framework for 
including HTA evidence in health care decision-making on different levels, focusing on bridging 
the gap between HTA research and policy uptake on the one hand, and ensuring a more 
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